Although patient #3 represented above-average CR duration while receiving WT1 protein-based vaccinations, relapse of AML was detected after more than one year of molecular response, with a complete clonal switch: the clone at initial diagnosis harbored FLT3, NPM1 and SRSF2 mutations, while at the time of relapse, BRAF, KRAS and STAG2 mutations were detected (Fig. 2d). This evidence concerns the gene FLT3 and acute myeloid leukemia.